APTO Aptose Biosciences Inc
Price (delayed)
$0.1621
Market cap
$3.16M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.97
Enterprise value
$5.92M
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics
Highlights
The EPS has surged by 62% year-on-year and by 32% since the previous quarter
Aptose Biosciences's net income has increased by 27% YoY and by 11% from the previous quarter
The quick ratio has decreased by 43% YoY but it has increased by 24% from the previous quarter
Key stats
What are the main financial stats of APTO
Market
Valuations
Earnings
Shares outstanding
19.52M
Market cap
$3.16M
Enterprise value
$5.92M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$36.2M
Net income
-$35.8M
EBIT
-$35.8M
EBITDA
-$35.38M
Free cash flow
-$37.16M
Per share
Balance sheet
Liquidity
EPS
-$2.97
EPS diluted
-$2.97
Free cash flow per share
-$2
Book value per share
-$0.5
Revenue per share
$0
TBVPS
$0.59
Total assets
$10.93M
Total liabilities
$20.06M
Debt
$10.72M
Equity
-$9.13M
Working capital
$477,000
Debt to equity
-1.17
Current ratio
1.05
Quick ratio
0.82
Net debt/EBITDA
-0.08
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-300.4%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-3,057.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
APTO stock price
How has the Aptose Biosciences stock price performed over time
Intraday
-14.68%
1 week
-9.94%
1 month
-25.54%
1 year
-91.19%
YTD
-28.05%
QTD
-28.05%
Financial performance
How have Aptose Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$36.2M
Net income
-$35.8M
Gross margin
N/A
Net margin
N/A
The company's operating income rose by 29% YoY and by 12% QoQ
Aptose Biosciences's net income has increased by 27% YoY and by 11% from the previous quarter
Growth
What is Aptose Biosciences's growth rate over time
Valuation
What is Aptose Biosciences stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 62% year-on-year and by 32% since the previous quarter
Efficiency
How efficient is Aptose Biosciences business performance
The return on assets has dropped by 110% year-on-year and by 7% since the previous quarter
Dividends
What is APTO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for APTO.
Financial health
How did Aptose Biosciences financials performed over time
The total assets is 46% smaller than the total liabilities
The company's total liabilities has surged by 53% YoY and by 53% QoQ
The total assets is down by 48% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.